COLLEGIUM PHARMACEUTICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.42 USD | +1.62% |
|
+4.54% | +18.32% |
| Apr. 11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
| Feb. 26 | Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 690 | 692.7 | 650 | 778.9 | 1,004 | 1,191 | - | - |
| Enterprise Value (EV) 1 | 531.5 | 775.7 | 650 | 778.9 | 1,004 | 1,358 | 1,149 | 1,191 |
| P/E ratio | -30.3 x | 26.4 x | 10 x | -31.4 x | 23.9 x | 12.3 x | 9.92 x | 8.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.33 x | 2.23 x | 2.35 x | 1.68 x | 1.77 x | 2.04 x | 2 x | 2.11 x |
| EV / Revenue | 1.79 x | 2.5 x | 2.35 x | 1.68 x | 1.77 x | 2.33 x | 1.93 x | 2.11 x |
| EV / EBITDA | 70.6 x | 5.55 x | 5.49 x | 2.93 x | 2.74 x | 3.52 x | 2.93 x | 3.22 x |
| EV / FCF | 24.9 x | - | - | - | 3.66 x | 4.66 x | 3.69 x | - |
| FCF Yield | 4.02% | - | - | - | 27.3% | 21.5% | 27.1% | - |
| Price to Book | - | - | - | - | - | 6.03 x | 4.62 x | - |
| Nbr of stocks (in thousands) | 33,527 | 34,582 | 34,797 | 33,572 | 32,611 | 32,706 | - | - |
| Reference price 2 | 20.58 | 20.03 | 18.68 | 23.20 | 30.78 | 36.42 | 36.42 | 36.42 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 296.7 | 310 | 276.9 | 463.9 | 566.8 | 583.5 | 595.9 | 565.2 |
| EBITDA 1 | 7.532 | 139.7 | 118.3 | 266 | 367 | 386 | 392.4 | 369.8 |
| EBIT 1 | -23.75 | 56.23 | 17.63 | 33.32 | 167 | 214.8 | 227.9 | 232 |
| Operating Margin | -8% | 18.14% | 6.37% | 7.18% | 29.46% | 36.82% | 38.24% | 41.05% |
| Earnings before Tax (EBT) 1 | -22.72 | 27.58 | -3.374 | -28.85 | 75.73 | 167.4 | 199.1 | 233.8 |
| Net income 1 | -22.72 | 26.75 | 71.52 | -25 | 48.16 | 116.2 | 144.3 | 174.3 |
| Net margin | -7.66% | 8.63% | 25.83% | -5.39% | 8.5% | 19.92% | 24.22% | 30.85% |
| EPS 2 | -0.6800 | 0.7600 | 1.860 | -0.7400 | 1.290 | 2.952 | 3.670 | 4.440 |
| Free Cash Flow 1 | 21.34 | - | - | - | 274.3 | 291.6 | 311.2 | - |
| FCF margin | 7.19% | - | - | - | 48.4% | 49.97% | 52.23% | - |
| FCF Conversion (EBITDA) | 283.39% | - | - | - | 74.74% | 75.53% | 79.31% | - |
| FCF Conversion (Net income) | - | - | - | - | 569.59% | 250.82% | 215.62% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 78.84 | 27.36 | 83.75 | 123.5 | 127 | 129.6 | 144.8 | 135.5 | 136.7 | 149.7 | 147.5 | 142.2 | 143.8 | 150 | 152.3 |
| EBITDA 1 | 37.34 | -4.478 | 43.53 | 71.18 | 74.87 | 76.44 | 87.62 | 85.81 | 89.39 | 104.2 | 94.9 | 92.82 | 95.58 | 102.8 | 97.44 |
| EBIT 1 | 14.15 | -34.12 | -10.02 | 11.11 | 20.47 | 11.76 | 24.63 | 35.63 | 45.01 | 61.69 | 54.38 | 49.82 | 52.24 | 58.39 | 53.14 |
| Operating Margin | 17.95% | -124.71% | -11.96% | 8.99% | 16.11% | 9.07% | 17.01% | 26.29% | 32.93% | 41.2% | 36.86% | 35.03% | 36.33% | 38.93% | 34.88% |
| Earnings before Tax (EBT) 1 | 9.037 | -38.88 | -15.84 | -6.646 | 1.432 | -7.791 | -17.56 | 17.8 | 28.78 | 46.71 | 40.77 | 37.36 | 40.97 | 48.31 | 42.46 |
| Net income 1 | 8.046 | -25.03 | -13.07 | -5.191 | 0.457 | -7.199 | -17.43 | 13.01 | 20.63 | 31.94 | 25.66 | 24.66 | 29.29 | 36.64 | 31.42 |
| Net margin | 10.21% | -91.49% | -15.6% | -4.2% | 0.36% | -5.55% | -12.04% | 9.6% | 15.09% | 21.33% | 17.39% | 17.34% | 20.37% | 24.43% | 20.62% |
| EPS 2 | 0.2200 | -0.7300 | -0.3900 | -0.1500 | 0.0100 | -0.2200 | -0.5100 | 0.3400 | 0.6100 | 0.8200 | 0.6475 | 0.6250 | 0.7500 | 0.9350 | 0.8200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 5/10/22 | 8/4/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/7/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 83 | - | - | - | 167 | - | - |
| Net Cash position 1 | 159 | - | - | - | - | - | 42.2 | - |
| Leverage (Debt/EBITDA) | - | 0.594 x | - | - | - | 0.4328 x | - | - |
| Free Cash Flow 1 | 21.3 | - | - | - | 274 | 292 | 311 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | 46.9% | 41.6% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | 10.4% | 12% | - |
| Assets 1 | - | - | - | - | - | 1,118 | 1,203 | - |
| Book Value Per Share 2 | - | - | - | - | - | 6.040 | 7.880 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 6.44 | 5.55 | 1.94 | 1.62 | 0.46 | 0.7 | 0.7 | 1 |
| Capex / Sales | 2.17% | 1.79% | 0.7% | 0.35% | 0.08% | 0.12% | 0.12% | 0.18% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
36.42
USD
Average target price
40
USD
Spread / Average Target
+9.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.32% | 1.19B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- COLL Stock
- Financials Collegium Pharmaceutical, Inc.
